Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
This guide highlights the different features in EPiC, helping you to navigate through the dashboard. Our worked example shows how EPiC can be used to carry out quality improvement activities.
View online or click the print-ready version.
The antihypertensive medicine Accuretic (quinapril with hydrochlorothiazide) is being withdrawn (Pfizer pulled stock from distribution on 31 October 2022).
Prescribers are advised to change patients from Accuretic to alternative medicine(s) with some urgency. Read our article for dose equivalence tables and information on switching, monitoring, co-payments and consultation fees.
Although triple therapy can reduce the risk of recurrent CVD events by at least 50 per cent over five years, the He Ako Hiringa EPiC dashboard indicates only half of people receive all three types of medicines following a CVD event. Read our latest bulletin for more on triple therapy and team-based initiatives that may help identify and prioritise patients for intensive management.
With recent funding changes to adalimumab, prescribers are being urged to change patients from Humira (the reference biological) to Amgevita (a biosimilar). We’ve collated this list of questions and answers, with links to other useful resources, to help inform your conversations with colleagues and patients.
FOCUS magazine showcases a selection of our original resources. You can use the educational content featured in FOCUS to identify and reduce barriers that prevent people from accessing the medicines they need.
This editable PDF helps you to delve into the EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions.
*New audit section*
An additional audit/CQI section allows you or your practice team to repeat the process, completing activities that may be used for Foundation Standard or the Cornerstone CQI or Equity modules.
Managers within healthcare provider services are vital to leading activity that promotes achieving equity of outcomes. Genuine management guidance is crucial to reduce bias and improve the health experience for individuals, whānau, and our communities.
Nirmatrelvir with ritonavir (Paxlovid), a new oral antiviral medicine for adults with COVID-19, is now available for community use. In people at higher risk of severe illness from COVID-19, treatment with Paxlovid has been shown to reduce the incidence of hospitalisation or death. However, for certain patients it will not be safe or appropriate to use Paxlovid.
This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.
This editable PDF helps you to delve into the EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions.
*New audit section*
An additional audit/CQI section allows you or your practice team to repeat the process, completing activities that may be used for Foundation Standard or the Cornerstone CQI or Equity modules.
This editable PDF helps you to delve into the EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions.
*New audit section*
An additional audit/CQI section allows you or your practice team to repeat the process, completing activities that may be used for Foundation Standard or the Cornerstone CQI or Equity modules.
This short video explores what patients think about the move to Amgevita. We spoke to a group of seven New Zealanders living with arthritis to find out how they feel about changing from the biological reference medicine, Humira, to the new biosimilar medicine, Amgevita.